Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 6/20 | 0.48 |
| ▸ | HTR2C | P28335 | 6/20 | 0.43 |
| ▸ | HTR2B | P41595 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491014 | 0.92 | EIF2AK3 (0.50) | EIF2AK3HTR2CHTR2BHTR2AMAPT | |
| SCHEMBL6500118 | 0.92 | HTR2C (0.49) | EIF2AK3HTR2CHTR2BHTR2AIDO1 | |
| SCHEMBL6489031 | 0.91 | HTR2A (0.51) | EIF2AK3HTR2CHTR2BHTR2A | |
| SCHEMBL6499110 | 0.91 | EIF2AK3 (0.49) | EIF2AK3HTR2CHTR2BHTR2AMAPT | |
| SCHEMBL6498678 | 0.91 | EIF2AK3 (0.49) | EIF2AK3HTR2CHTR2BHTR2AMAPT | |
| SCHEMBL6490739 | 0.91 | EIF2AK3 (0.49) | EIF2AK3HTR2CHTR2BHTR2AMAPT | |
| SCHEMBL6490743 | 0.91 | EIF2AK3 (0.49) | EIF2AK3HTR2CHTR2BHTR2AMAPT | |
| SCHEMBL6489395 | 0.90 | HTR2A (0.50) | EIF2AK3HTR2CHTR2BHTR2A | |
| SCHEMBL6488120 | 0.90 | HTR2A (0.50) | EIF2AK3HTR2CHTR2BHTR2A | |
| SCHEMBL6489398 | 0.90 | HTR2A (0.50) | EIF2AK3HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | EIF2AK3 2638/4885HTR2C 2433/4885HTR2B 928/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | EIF2AK3 3626/4885HTR2C 1453/4885HTR2B 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.